Adlai Nortye (ANL) is a US-listed Healthcare company in Biotechnology with a market capitalization of $679M, trading at
2.80 on the NASDAQ. This SniperIQ fundamentals page covers Adlai Nortye's valuation, profitability (net margin -343.9%), revenue ($5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$679M
Net Margin-343.9%
Revenue (FY25)$5M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Adlai Nortye's market cap?
Adlai Nortye (ANL) has a market capitalization of approximately $679M, trading at
2.80 on the NASDAQ. Market cap moves with the live share price.
How profitable is Adlai Nortye?
Adlai Nortye runs a net profit margin of -343.9%, a gross margin of 100.0%, and an operating margin of -330.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Adlai Nortye generate?
Adlai Nortye reported revenue of $5M for fiscal year 2025, with net income of -
6M and earnings per share (EPS) of -3.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Adlai Nortye pay a dividend?
Adlai Nortye does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Adlai Nortye financially healthy?
Adlai Nortye carries a debt-to-equity ratio of -3.17x and a current ratio of 0.65x, with a market beta of 1.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Adlai Nortye a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Adlai Nortye (ANL) the key facts are: market cap $679M, revenue $5M, 52-week range 0.879-17.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Adlai Nortye's full fundamentals live
Get Adlai Nortye's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.